Pharmaceutical - Asia-Pacific, Sanofi


Current filters:


Popular Filters

Sanofi Pasteur inks deal with Korea’s SK Chemical on vaccines

Sanofi Pasteur inks deal with Korea’s SK Chemical on vaccines


In a second collaboration in less than a month, Sanofi Pasteur, the vaccines division of French drug…

Asia-PacificLicensingPharmaceuticalResearchSanofiSanofi PasteurSK ChemicalVaccines

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market


From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

New Zealand reaches agreement with Sanofi to fund ALS drug


New Zealand's Pharmaceutical Management Agency PHARMAC has announce the approval of an agreement with…

Asia-PacificNeurologicalPharmaceuticalRare diseasesRegulationRilutekSanofi

China starts investigation of alleged bribery by Sanofi


Following last week's whistleblower allegations that French drug major Sanofi (Euronext: SAN) had paid…

Asia-PacificLegalMarkets & MarketingPharmaceuticalPricingSanofi

Sanofi latest to be implicated Chinese bribery allegations


In the wake of allegations that several multinational pharma companies have engaged in unlawful marketing…

Asia-PacificLegalLundbeckMarkets & MarketingNovo NordiskPharmaceuticalSanofi

New Zealand to widen access for type 1 and type 3 Gaucher disease drug


New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of a proposal to widen…

Asia-PacificBiotechnologyCerezymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Takeda gains Chinese approval for diabetes drug


Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502), says that the China Food and Drug Administration…

Asia-PacificDiabetesNesinaPharmaceuticalRegulationSanofiTakeda Pharmaceuticals

India's NPPA says drugmakers cannot raise prices of imported products


At a meeting earlier this month, India's drug price regulator the National Pharmaceutical Pricing Authority…


Sanofi to invest $75 million in Vietnam facility; views Chinese expansion


French drug major Sanofi (Euronext: SAN) announced the official launch of a construction project for…


Sanofi eyes big plans for China


French pharmaceutical giant Sanofi (Euronext: SAN) plans to complete building a large plant for the production…

Asia-PacificPharmaceuticalProductionSanofiSanofi PasteurVaccines

Chinese diabetes market worth $2.2 billion, with over 50% accounted for by insulin


Demand within the Chinese insulin market has grown at a fast pace in the past decade. Over the next five…

Asia-PacificDiabetesEli LillyMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Japan's seasonal flu vaccines market analysis


The Japanese influenza vaccine market is valued at around $702 million in 2012, according to a new report…

Anti-viralsAsia-PacificGlaxoSmithKlineMarkets & MarketingPharmaceuticalSanofiVaccines

Australian launch for Sanofi Pasteur's Imojev, first single-dose vaccine against Japanese encephalitis


Sanofi Pasteur, the vaccines division of Sanofi (Euronext: SAN) has launched its Imojev vaccine against…

Asia-PacificImojevMarkets & MarketingPharmaceuticalSanofiSanofi PasteurVaccines

Sanofi MS drug Aubagio gets second approval, in Australia


Having already gained approval in the largest global pharma market, the USA, French drug major Sanofi's…


Chugai licenses SGLT2 inhibitor CSG452 in Japan to Kowa and Sanofi


Japanese drugmaker Chugai Pharmaceutical (TYO: 4519), which is majority owned by Swiss major Roche (ROG:…

Asia-PacificChugai PharmaceuticalCSG452DiabetesKowa PharmaceuticalsLicensingPharmaceuticalRocheSanofi

Alnylam gets upfront $22.5 million in RNAi link with Genzyme


French drug major Sanofi's (Euronext: SAN) US biotech subsidiary Genzyme has entered into an exclusive…

Alnylam PharmaceuticalsAsia-PacificBiotechnologyGenzymeLicensingPharmaceuticalRare diseasesSanofi

Analyst insight: Sanofi eyes Columbia, Indonesia and Vietnam


Emerging markets, BRIC countries are words that have recently risen to prominence in a majority of pharmaceutical…

Asia-PacificLicensingMarkets & MarketingMergers & AcquisitionsPharmaceuticalSanofiSouth America

New Zealand's PHARMAC agrees pricing deal with Sanofi for Arava


New Zealand's national pharmaceuticals funding agency, PHARMAC, has announced changes to the listings…


Sanofi moves on Lemtrada; Novartis Indian patent case


French drug major Sanofi's (Euronext: SAN) USA-based rare diseases subsidiary Genzyme is pulling leukemia…

Asia-PacificCampathEuropeGenzymeGlivecLegalLemtradaMarkets & MarketingNorth AmericaNovartisPatentsPharmaceuticalSanofi

Sanofi files for Japanese approval of diabetes drug Lyxumia


French drug major Sanofi (Euronext: SAN), has submitted a marketing authorization application for lixisenatide…

Asia-PacificDiabeteslixisenatideLyxumiaPharmaceuticalRegulationSanofiZealand Pharma

Sanofi inaugurates Lantus SoloSTAR Pen assembly plant in China


French drug major Sanofi (Euronext: SAN) revealed this morning that it has inaugurated a new assembling…

Asia-PacificDiabetesLantusMarkets & MarketingPharmaceuticalSanofi

China’s acute coronary syndrome drug market forecast to grow to nearly $450 million in 2015


The acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million…

Asia-PacificAstraZenecaBrilintaCardio-vascularEffientEli LillyMarkets & MarketingPharmaceuticalPlavixSanofi

Sanofi oral MS drug Aubagio shows strong efficacy in Ph III trial; plans massive Indian vaccine plant


French drug major Sanofi (Euronext: SAN) and its subsidiary Genzyme says that the results of a pivotal…


Company Spotlight



Back to top